An interventional study of Platelet-rich plasma and Physiologic saline in Platelets Rich Plasma, Saline and Myofascial Pain, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
The aim of this is to compare the usage of Platelet-Rich Plasma (PRP) and Physiologic Saline injection in management of myofascial pain dysfunction (MPD).
Myofascial Pain Syndrome (MPS) is a chronic pain disorder characterized by the presence of myofascial trigger points (TrPs), which are hypersensitive areas within the muscle or its surrounding fascia. These trigger points are typically associated with tight bands of muscle fibers and can cause localized and referred pain when compressed or stimulated.
MPS can affect any age group and is a significant cause of musculoskeletal pain, disability, and reduced quality of life. Its prevalence varies, with estimates suggesting it may impact up to 85% of individuals with chronic pain conditions. Despite its widespread occurrence, MPS often goes unrecognized due to its overlap with other pain disorders, such as fibromyalgia, tension headaches, or nerve-related conditions.
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
This study's planned enrollment of 28 is below the median of 66 across 8,493 interventional studies indexed under Pain.
Browse Pain studies →Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with platelet-rich plasma (PRP) injection.
Drug: Platelet-rich plasma
Patients will be managed with physiologic saline injection.
Drug: Physiologic saline
Patients will be treated with platelet-rich plasma (PRP) injection.
Patients will be managed with physiologic saline injection.
Degree of pain
Pain level will be evaluated by using of Visual Analog Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")
Time frame: 24 weeks postoperatively
Mean maximum unassisted mouth opening (MUMO)
Maximum distance between the incisal edges of the upper and lower central incisors during mouth opening will be measured in millimeters. Higher values indicate greater mouth opening.
Time frame: 24 weeks postoperatively
Mean maximum assisted mouth opening (MAMO)
Maximum distance between the incisal edges of the upper and lower central incisors during mouth opening will be measured in millimeters. Higher values indicate greater mouth opening.
Time frame: 24 weeks postoperatively
Range of right lateral excursive movements
Maximum voluntary lateral movement of the mandible to the right will be measured in millimeters as the displacement of the lower dental midline relative to the upper dental midline from the starting position. Higher values indicate greater lateral mandibular mobility.
Time frame: 24 weeks postoperatively
Range of left lateral excursive movements
Maximum voluntary lateral movement of the mandible to left will be measured in millimeters as the displacement of the lower dental midline relative to the upper dental midline from the starting position. Higher values indicate greater lateral mandibular mobility.
Time frame: 24 weeks postoperatively
Range of protrusive movement
Maximum voluntary forward movement of the mandible from the starting bite position will be measured in millimeters and accounting for the initial horizontal relationship between the upper and lower incisors (overjet). Higher values indicate greater protrusive mandibular mobility.
Time frame: 24 weeks postoperatively
Degree of patient satisfaction
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Time frame: 24 weeks postoperatively
Range of mandibular motion
Range of mandibular motion will be assessed quantitatively with the help of digital vernier calipers (in millimeters).
Time frame: 24 weeks postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
Of 3,731 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 12 months is above that.
Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma